SEQSTER, a healthcare technology company, and Praxis Precision Medicines Inc. have expanded their partnership to accelerate clinical trials, data collection, and real-world evidence (RWE) generation across Praxis’ clinical development programs.

Building on early success in Praxis’ innovative Essential3 Program for Essential Tremor, SEQSTER’s platform continues to support the broader ENERGY program, Praxis’ comprehensive program advancing vormatrigine for the treatment of epilepsy.

SEQSTER’s platform provides Praxis with automated access to patient-consented electronic health records from across the U.S. healthcare system, supporting patient screening, enrollment, and ongoing data collection for its EMPOWER observational study. The ENERGY program, which includes EMPOWER and the POWER clinical studies, has attracted approximately 5,000+ patients with epilepsy.

“At Praxis, we are committed to delivering life-altering treatments to patients with CNS disorders faster and more effectively than has ever been done before,” said Megan Sniecinski, COO, Praxis Precision Medicines. “SEQSTER has been a foundational element of our clinical trial execution, enabling more efficient trial enrollment while capturing the longitudinal real-world data we need to advance our programs. Our partnership represents a shared commitment to delivering better outcomes for patients and driving forward innovative ways to accelerate clinical research.”

“Praxis represents exactly the kind of innovative sponsor we built SEQSTER to support. One that understands the value of real-world data and is willing to rethink how clinical trials are conducted,” said Ardy Arianpour, CEO of SEQSTER. “We’re proud to have earned their trust across multiple studies and look forward to continuing this partnership as they bring transformative therapies to patients with CNS disorders.”